South Dakota Investment Council lowered its holdings in Medtronic PLC (NYSE:MDT – Free Report) by 2.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 243,131 shares of the medical technology company’s stock after selling 6,215 shares during the period. South Dakota Investment Council’s holdings in Medtronic were worth $20,980,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of MDT. First Eagle Investment Management LLC raised its position in shares of Medtronic by 37.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after purchasing an additional 3,739,288 shares during the period. Cullen Capital Management LLC acquired a new position in Medtronic during the 2nd quarter valued at approximately $202,764,000. State Street Corp boosted its position in Medtronic by 2.7% during the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after purchasing an additional 1,658,301 shares during the period. Amundi boosted its position in Medtronic by 36.3% during the 1st quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock valued at $525,986,000 after purchasing an additional 1,616,739 shares during the period. Finally, Bank of America Corp DE grew its stake in Medtronic by 5.4% during the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after buying an additional 1,343,220 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.
Key Stories Impacting Medtronic
These are some of the MDT stories that stood out recently:
- Positive Sentiment: The FDA cleared Medtronic’s Hugo robotic-assisted surgery system for general surgery in the U.S. The expanded authorization opens access to an estimated 3.5 million annual U.S. cases and procedures that represent more than half of U.S. soft-tissue surgeries, increasing Hugo’s commercial opportunity. Article: Medtronic’s Hugo robot gets expanded FDA clearance in general surgery
- Positive Sentiment: Medtronic plans to acquire Contego Medical for $380 million, adding carotid and peripheral vascular technologies to its portfolio. The deal builds on an existing U.S. distribution relationship and could strengthen its vascular-intervention business. Article: Medtronic to buy Contego Medical for $380M
- Neutral Sentiment: A preview of Medtronic’s Q2 results points to Cardiovascular momentum, particularly cardiac ablation, with Neuroscience and Diabetes also expected to contribute growth. These are expectations ahead of the earnings report, not reported results. Article: MDT Q2 Earnings Preview
Analysts Set New Price Targets
MDT has been the topic of several analyst reports. Stifel Nicolaus increased their target price on Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research report on Wednesday, September 2nd. Weiss Ratings upgraded Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 19th. Needham & Company LLC reissued a “buy” rating on shares of Medtronic in a report on Thursday, September 17th. Bank of America upped their price target on shares of Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, September 2nd. Finally, Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Monday. Nineteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.28.
View Our Latest Stock Analysis on MDT
Medtronic Stock Performance
MDT opened at $102.24 on Wednesday. The business’s 50 day moving average is $94.09 and its 200-day moving average is $88.49. The stock has a market cap of $130.78 billion, a PE ratio of 25.18, a price-to-earnings-growth ratio of 2.41 and a beta of 0.56. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33.
Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the previous year, the firm posted $1.26 earnings per share. The business’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, analysts predict that Medtronic PLC will post 5.98 earnings per share for the current year.
Medtronic Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were paid a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 2.8%. Medtronic’s payout ratio is presently 70.94%.
Insiders Place Their Bets
In other news, CEO Geoffrey Martha sold 50,000 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the transaction, the chief executive officer owned 277,866 shares of the company’s stock, valued at approximately $26,397,270. This represents a 15.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of the firm’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the transaction, the executive vice president directly owned 105,916 shares in the company, valued at $10,167,936. This trade represents a 8.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is owned by company insiders.
Medtronic Company Profile
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Further Reading
- Five stocks we like better than Medtronic
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
